PanGIA Logo

Revolutionizing Cancer Detection with
The True Liquid Biopsy

Quick, Non-Invasive Test with Superior Sensitivity and Specificity

Who We Are

PanGIA Biotech

Welcome to PanGIA Biotech, a leading biotechnology company at the forefront of true liquid biopsy technology. We are dedicated to transforming disease and cancer detection through our innovative and groundbreaking solutions. With our expertise and commitment to research, we aim to make a significant impact by empowering patients and healthcare providers with powerful detection tools.

At PanGIA, our team believes in the power of the true liquid biopsy. Our team of scientists, researchers, and industry experts have developed cutting-edge methods to detect and analyze cancer-related biomarkers in urine. By harnessing the potential of the true liquid biopsy, we can provide accurate, non-invasive, and personalized diagnostic solutions for early cancer detection, treatment selection, and monitoring.

What if it were possible to detect and distinguish different cancers in early-stage disease when response to therapy is greatest,
using a non-invasive urine specimen?

The Solution

True Liquid Biopsy Platform

PanGIA is a white space, urine based, non-invasive, machine learning driven, biomolecular profile true liquid biopsy platform.

Our true liquid biopsy platform allows rapid development of non-invasive testing for detecting and managing a variety of diseases and disorders, including cancers. Our sophisticated algorithms and bioinformatics tools enable the interpretation and extraction of meaningful insights from complex data.

One of the key advantages of our true liquid biopsy technology is its non-invasive nature. Unlike common traditional and liquid biopsies that require invasive procedures, our tests do not require a blood draw or procedure. This minimizes patient discomfort, reduces procedural risks, and allows for serial monitoring of the disease progression and treatment response. Our technology empowers both patients and healthcare professionals with actionable information for informed decision-making.

Our Mission

Early Detection is the CURE

PanGIA Biotech’s true liquid biopsy products are designed to meet the diverse needs of patients, physicians, and researchers. Our solutions are tailored to various cancer types, diseases, and disorders, ensuring accurate and actionable results.

By leveraging state-of-the-art technologies and rigorous quality control processes, the true liquid biopsy tests deliver exceptional sensitivity, specificity, and reliability. Whether you are looking for early cancer detection, therapy selection, monitoring treatment response, or detecting minimal residual disease, our products are designed to support patients throughout the entire journey.

Improved early detection of cancers, especially in early stages (Stage 1-2)

Improve quality of life

Drive wellness through earlier intervention

Patients and clinicians would overwhelmingly prefer a quick, non-invasive test with superior sensitivity and specificity.

Reduce Unnecessary Biopsies

Improve Diagnostic Yield

Reduce Costs

Fewer Complications and Side Effects

PanGIA combines a machine learning algorithm with proprietary unbiased binding of small molecules, proteins, and cells, followed by a signal readout and final analysis, creating a biomolecular profile of the patient.

PanGIA Platform

True Liquid Biopsy Pipeline

PanGIA Prostate

PanGIA Breast

PanGIA Ovarian

PanGIA Lung

PanGIA Renal

PanGIA Bladder

PanGIA Colorectal

PanGIA Stomach

PanGIA Pancreas

PanGIA Liver

PanGIA Brain

& more!

Disruptive Innovation Use Case

PanGIA Platform

PanGIA is a white space, urine based, non-invasive, machine learning driven, biomolecular profile testing platform.

Value to Patients

→ Improved predictive profile over PSA / other screening tests
→ Avoidance or warranted delay of invasive procedures

Value to Physicians

→ Additional data points for identifying candidates for biopsies
→ Improved outcomes from missing fewer cancers and reduced side effects

Value to Payers

→ Avoidance of unnecessary biopsies
→ Avoidance of costs for side effects